Prospective prenatal serum screening for Down syndrome in Venezuela

被引：3

作者：

Alvarez-Nava, Francisco ^{[1
]}

Sotop, Marisol ^{[1
]}

Morales-Machin, Alisandra ^{[1
]}

Rojas, Alicia ^{[1
]}

Urdaneta, Karelis ^{[1
]}

Canizalez, Jenny ^{[1
]}

机构：

[1] Univ Zulia, Fac Med, Unidad Genet Med, Maracaibo 4001A, Estado Zulia, Venezuela

来源：

INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS | 2008年 / 103卷 / 03期

关键词：

Fetal Down syndrome; Prenatal diagnosis; Prospective study; Risk estimate; Second-trimester maternal serum screening;

D O I：

10.1016/j.ijgo.2008.07.017

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Objective: To assess the usefulness of triple-marker screening for Down syndrome in Venezuela. Method: Maternal serum concentrations of alpha fetoprotein (AFP), beta human chorionic gonadotropin (beta-hCG), and unconjugated estriol (uE3) were measured weekly in 3895 women from the 15th to the 20th week of pregnancy. Population-specific likelihood ratios were determined and used to calculate the risk of fetal Down syndrome for each pregnancy. Results: The median multiple of the median values for AFP, beta-hCG, and uE3 concentrations were 0.69, 2.10, and 0.67 for the affected pregnancies. The likelihood ratio for a positive result was 1:19. The detection and false-positive rates were 69.23% and 5.8%. Conclusion: These findings were consistent with reported data and therefore confirmed triple-marker serum screening as effective and suitable for prenatal care in Venezuela. Latin American governments and Health Agencies should recommend offering this screening method to all pregnant women. (c) 2008 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.

引用

页码：241 / 245

页数：5

共 14 条

[1]

Cavalli P, 1998, PRENATAL DIAG, V18, P637, DOI 10.1002/(SICI)1097-0223(199806)18:6<637::AID-PD295>3.0.CO

[2]

2-X

[3] Biochemical screening for Down syndrome [J].

Cuckle, H .

EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2000, 92 (01) :97-101

[4] Screening for trisomy 21 in Flanders: a 10 years review of 40.490 pregnancies screened by maternal serum [J].

Gyselaers, WJA ;

Vereecken, AJ ;

Van Herck, EJH ;

Straetmans, DPL ;

Martens, GEI ;

de Jonge, ETM ;

Ombelet, WUAM ;

Nijhuis, JG .

EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2004, 115 (02) :185-189

[5] REDUCING THE NEED FOR AMNIOCENTESIS IN WOMEN 35 YEARS OF AGE OR OLDER WITH SERUM MARKERS FOR SCREENING [J].

HADDOW, JE ;

PALOMAKI, GE ;

KNIGHT, GJ ;

CUNNINGHAM, GC ;

LUSTIG, LS ;

BOYD, PA .

NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (16) :1114-1118

[6] Current state of screening for Down's syndrome [J].

Holding, S .

ANNALS OF CLINICAL BIOCHEMISTRY, 2002, 39 :1-11

[7]

Hsieh Tsang-Tang, 2007, Taiwan J Obstet Gynecol, V46, P230, DOI 10.1016/S1028-4559(08)60025-X

[8] Second trimester trisomy 21 maternal serum marker screening. Results of a countrywide study of 854902 patients [J].

Muller, F ;

Forestier, F ;

Dingeon, B .

PRENATAL DIAGNOSIS, 2002, 22 (10) :925-929

[9]

NORGAARDPEDERSEN B, 1990, CLIN GENET, V37, P35

[10] IMPROVED PERFORMANCE IN A PRENATAL SCREENING-PROGRAM FOR DOWNS-SYNDROME INCORPORATING SERUM-FREE HCG-SUBUNIT ANALYSES [J].

RYALL, RG ;

STAPLES, AJ ;

ROBERTSON, EF ;

POLLARD, AC .

PRENATAL DIAGNOSIS, 1992, 12 (04) :251-261

← 1 2 →